0.00Open1.84Pre Close0 Volume5 Open Interest2.50Strike Price0.00Turnover121.34%IV3.95%PremiumDec 20, 2024Expiry Date1.68Intrinsic Value100Multiplier23DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.9674Delta0.0572Gamma2.46Leverage Ratio-0.0023Theta0.0015Rho2.38Eff Leverage0.0008Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet